Screening compound: InChI=1S/C20H13ClN4O4/c21-14-4-2-1-3-13(14)20-22-18(29-24-20)10-25-19(26)8-6-15(23-25)12-5-7-16-17(9-12)28-11-27-16/h1-9H,10-11H2

Screening compound: InChI=1S/C20H13ClN4O4/c21-14-4-2-1-3-13(14)20-22-18(29-24-20)10-25-19(26)8-6-15(23-25)12-5-7-16-17(9-12)28-11-27-16/h1-9H,10-11H2
Screening compound: InChI=1S/C20H13ClN4O4/c21-14-4-2-1-3-13(14)20-22-18(29-24-20)10-25-19(26)8-6-15(23-25)12-5-7-16-17(9-12)28-11-27-16/h1-9H,10-11H2 alternative view

Chemical Structure Depiction of ChemDiv screening compound
InChI=1S/C20H13ClN4O4/c21-14-4-2-1-3-13(14)20-22-18(29-24-20)10-25-19(26)8-6-15(23-25)12-5-7-16-17(9-12)28-11-27-16/h1-9H,10-11H2

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

F839-0156

Molecular Formula

C20H13ClN4O4 (C20 H13 ClN4 O4)

Compound Name

6-(2H-1,3-benzodioxol-5-yl)-2-{[3-(2-chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl}-2,3-dihydropyridazin-3-one

IUPAC name

6-(2H-13-benzodioxol-5-yl)-2-{[3-(2-chlorophenyl)-124-oxadiazol-5-yl]methyl}-23-dihydropyridazin-3-one

SMILES

O=C(C=C1)N(Cc2nc(-c(cccc3)c3Cl)no2)N=C1c(cc1)cc2c1OCO2

InChI

InChI=1S/C20H13ClN4O4/c21-14-4-2-1-3-13(14)20-22-18(29-24-20)10-25-19(26)8-6-15(23-25)12-5-7-16-17(9-12)28-11-27-16/h1-9H,10-11H2

InChI Key

KBQMNMYUCDTCEK-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD27198628

InChI=1S/C20H13ClN4O4/c21-14-4-2-1-3-13(14)20-22-18(29-24-20)10-25-19(26)8-6-15(23-25)12-5-7-16-17(9-12)28-11-27-16/h1-9H,10-11H2 in Drug Discovery

Included in Screening Libraries

Anti-Inflammatory Library (24602 compounds)

Anticancer Library (62698 compounds)

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

C-Met Library (15277 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Immune system
  • Cancer
  • Cancer
  • Digestive system
  • Respiratory tract
  • Otorhinolaryngologic
  • Endocrine
Targets:
  • Kinases
Mechanism of action:
  • Receptor's ligands

References: we are preparing a list of scientific research reports with InChI=1S/C20H13ClN4O4/c21-14-4-2-1-3-13(14)20-22-18(29-24-20)10-25-19(26)8-6-15(23-25)12-5-7-16-17(9-12)28-11-27-16/h1-9H,10-11H2 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound InChI=1S/C20H13ClN4O4/c21-14-4-2-1-3-13(14)20-22-18(29-24-20)10-25-19(26)8-6-15(23-25)12-5-7-16-17(9-12)28-11-27-16/h1-9H,10-11H2?
Check Price and Availability of InChI=1S/C20H13ClN4O4/c21-14-4-2-1-3-13(14)20-22-18(29-24-20)10-25-19(26)8-6-15(23-25)12-5-7-16-17(9-12)28-11-27-16/h1-9H,10-11H2, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of InChI=1S/C20H13ClN4O4/c21-14-4-2-1-3-13(14)20-22-18(29-24-20)10-25-19(26)8-6-15(23-25)12-5-7-16-17(9-12)28-11-27-16/h1-9H,10-11H2 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for InChI=1S/C20H13ClN4O4/c21-14-4-2-1-3-13(14)20-22-18(29-24-20)10-25-19(26)8-6-15(23-25)12-5-7-16-17(9-12)28-11-27-16/h1-9H,10-11H2
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for InChI=1S/C20H13ClN4O4/c21-14-4-2-1-3-13(14)20-22-18(29-24-20)10-25-19(26)8-6-15(23-25)12-5-7-16-17(9-12)28-11-27-16/h1-9H,10-11H2
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of InChI=1S/C20H13ClN4O4/c21-14-4-2-1-3-13(14)20-22-18(29-24-20)10-25-19(26)8-6-15(23-25)12-5-7-16-17(9-12)28-11-27-16/h1-9H,10-11H2 available by request